GYNE-LOTRIMIN 3 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 COMBINATION PACK (GYNE-LOTRIMIN 3 COMBINATION PACK).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability. The combination pack includes an insert for vaginal use and a topical cream for external use.
| Metabolism | Hepatic metabolism to inactive metabolites, primarily via oxidation and glucuronidation. Vaginal absorption minimal; systemic exposure low. |
| Excretion | Clotrimazole: ~0.03% of topical dose excreted renally as metabolites; majority eliminated in feces via biliary excretion. Vaginal administration: minimal systemic absorption (<3%), with absorbed drug primarily metabolized hepatically and excreted in bile/feces. |
| Half-life | Terminal half-life of absorbed clotrimazole is approximately 3.5-6 hours; clinically, topical application maintains local concentrations without reliance on systemic half-life. |
| Protein binding | Clotrimazole is ~90% bound to plasma proteins (albumin and alpha-1-acid glycoprotein) for the small fraction that enters systemic circulation. |
| Volume of Distribution | Apparent Vd is not clinically meaningful due to negligible systemic absorption. With intravenous data (not used clinically), Vd is ~2.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Vaginal administration: systemic bioavailability <3% (range 0.5-3%) due to minimal absorption through vaginal mucosa. Topical cream: negligible systemic absorption (<0.5%). |
| Onset of Action | Vaginal cream/tablet: symptom relief begins within 24-48 hours; clinical cure typically achieved after 3-day regimen. |
| Duration of Action | Local antimycotic effect persists for approximately 72 hours after last dose; complete eradication of Candida requires full 3-day course. |
Vaginal suppository: 200 mg at bedtime for 3 nights; topical cream (2%): apply intravaginally once daily for 3 nights.
| Dosage form | CREAM, TABLET |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Adolescents (≥12 years): same as adult dosing (200 mg vaginal suppository at bedtime for 3 nights or 2% cream intravaginally once daily for 3 nights). Children <12 years: not recommended. |
| Geriatric use | Same as adult dosing; no specific adjustments required. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 COMBINATION PACK (GYNE-LOTRIMIN 3 COMBINATION PACK).
| Breastfeeding | Clotrimazole: Minimal systemic absorption; no expected risk; M/P ratio not established for topical/vaginal use. Betamethasone: Enters breast milk; M/P ratio ~0.5-0.8 (for systemic); topical use low absorption, unlikely to cause effects. Use caution, avoid application to breasts. |
| Teratogenic Risk | Clotrimazole: Topical use not associated with increased risk of major birth defects; limited systemic absorption. Animal studies show no teratogenicity at doses up to 100 mg/kg. Vaginal administration has minimal absorption. Betamethasone: Corticosteroid; studies suggest slight increase in oral clefts with first trimester systemic use; risk with topical use is low due to low systemic absorption. Third trimester: Betamethasone may cause fetal adrenal suppression if used in high doses. Overall risk is low with combination pack as directed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to clotrimazole or any component of the formulation","Known or suspected pregnancy (unless clearly necessary)","Do not use in patients with vaginal trichomoniasis or bacterial vaginosis unless specifically treated for mixed infection"]
| Precautions | ["For intravaginal use only; not for oral or ophthalmic use","If no improvement in 3 days or symptoms persist >7 days, reevaluate diagnosis","Discontinue if hypersensitivity reactions occur","May cause vaginal irritation, burning, or cramping","Safety not established in pregnant women (Category C); use only if potential benefit outweighs risk","Do not use if abdominal pain, fever, or malodorous discharge present"] |
Loading safety data…
| Fetal Monitoring | No routine monitoring required for clotrimazole. For betamethasone: Monitor maternal blood glucose, fetal growth if repeated high doses; assess for symptoms of Cushing's syndrome in neonate if prolonged exposure. |
| Fertility Effects | No known effects on fertility from clotrimazole or betamethasone topical/vaginal use. |